How it works, simply
It activates GLP-1 and GIP receptors.
What the evidence tells us
Results in a selected diabetes population cannot be assumed to apply to obesity treatment or to replace insulin.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
This guide does not establish a safe dose, interaction profile or long-term safety for self-use. Effects reported for one route or formulation may not apply to another.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Activates GLP-1 and GIP receptors in metabolic research.
Sponsor or developer: Roche
Studied or labeled topics: Type 1 diabetes glycemic-control research
2026-04-23: Dated sponsor pipeline lists acmopatide (CT-868) in Phase 2 for type 1 diabetes glycemic control.
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- Roche: April 2026 development pipeline ↗ · Sponsor · 2026-04-23
Readability updated October 10, 2026. Evidence review: September 23, 2026 (listed facts only). A wording update is not a new clinical review.